CoChat

Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib

Younossi, Zobair M., Stepanova, Maria, Lawitz, Eric, Charlton, Michael, Loomba, Rohit, Myers, Robert P., Subramanian, Mani, McHutchison, John G., Goodman, Zachary · 2018 · Liver International
Cited by 85

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background: Patient‐reported outcomes (PRO s) represent patients’ perspective about their well‐being. Aim: To assess PRO changes in patients with non‐alcoholic steatohepatitis (NASH) after treatment with selonsertib (SEL) and to associate them with different biomarkers. Methods: Patients with NASH and stage 2‐3 fibrosis received SEL 6 mg or 18 mg orally QD alone or in combination with simtuzumab (SIM, 125 mg SC weekly) or SIM alone for 24 weeks. Biopsies were obtained at baseline and at treatment week 24. PRO s were assessed using SF‐36, CLDQ and WPAI:SHP. Results: Seventy‐two patients with NASH were included (54 ± 10 years, 31% male, 65% stage 3, 71% diabetes). Baseline physical health‐related PRO scores were significantly lower than population norms (P < .05). During treatment, there were no consistent differences in treatment‐emergent PRO changes between different regimens (P > .05). However, NASH subjects who experienced ≥2 decrease in NAFLD Activity Score or ≥1‐stage reduction in fibrosis showed significant improvements in their PRO s (up to +15.5% of a PRO range size, P < .05). Additionally, improvements in PRO s (up to +21.5%, P < .05) were noted in patients with at least 50% relative reduction in collagen, while NASH subjects with >17% increase in their collagen experienced PRO worsening (up to −13.9%, P < .05). Baseline serum CK‐18, IL‐6 and CRP significantly correlated with PRO s (rho from −0.24 to −0.38, P < .05). Conclusions: A decrease in hepatic collagen is the most prominently associated with improvement of PRO s in NASH patients with F2‐F3 treated with SEL. Furthermore, serum cytokines are associated with baseline PRO s and with treatment‐emergent changes in PRO s in patients with NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.13706

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 85

Metadata

Authors
Younossi, Z. M., Stepanova, M., Lawitz, E., Charlton, M., Loomba, R., Myers, R. P., Subramanian, M., McHutchison, J. G., & Goodman, Z.
Venue
Liver International
Publisher
Wiley
Published
2018-02-22
Volume
38
Issue
10
Pages
1849-1859
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2792505913
Cited by
85
References
8
FWCI
7.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib. https://app.cochat.ai/papers/10.1111/liv.13706
The paper
Younossi, Z. M., Stepanova, M., Lawitz, E., Charlton, M., Loomba, R., Myers, R. P., Subramanian, M., McHutchison, J. G., & Goodman, Z. (2018). Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib. Liver International. https://doi.org/10.1111/liv.13706

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.